Kiadis Pharma announces pos­i­tive reg­u­la­to­ry update on ATIR101™ and ATIR201™

~ Regulatory approval received from the nation­al author­i­ty in Belgium to start piv­otal Phase III tri­al with ATIR101™ and from the nation­al author­i­ty in Germany to start the Phase I/II tri­al with ATIR201™ ~

Amsterdam, The Netherlands, April 3, 2017, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell immunother­a­py treat­ments for blood can­cers and inher­it­ed blood dis­or­ders, today announces that it has obtained reg­u­la­to­ry approval from the nation­al author­i­ty in Belgium (the FAGG, the Federal Agency for Medicines and Health Products) to start its ran­dom­ized, con­trolled, transat­lantic Phase III clin­i­cal tri­al with ATIR101™ for acute leukemia (CR-AIR-009) in Belgium. In addi­tion, the Company has received reg­u­la­to­ry approval from the nation­al author­i­ty in Germany (the PEI, the Paul-Ehrlich-Institute) to start its Phase I/II clin­i­cal tri­al with ATIR201™ for tha­lassemia (CR-BD-001). This fol­lows after the pre­vi­ous Company announce­ment in February 2017 that the Phase III tri­al with ATIR101™ has been ini­ti­at­ed fol­low­ing reg­u­la­to­ry approval from the nation­al author­i­ty in Canada, and from the pre­vi­ous Company announce­ment at the end of 2016 that it had ini­ti­at­ed the Phase I/II tri­al with ATIR201™ after hav­ing obtained reg­u­la­to­ry approval from the nation­al author­i­ty in the United Kingdom.

Leave a Reply

Your email address will not be published. Required fields are marked *